Duloxetine Capsule, Delayed Release
Product Images NDC 50090-7812

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-7812). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Duloxetine Fig1)

A line graph depicting the proportion of patients with relapse over time (days) from randomization. It shows two treatment groups: Duloxetine and placebo. The y-axis represents the proportion of patients with relapse, ranging from 0 to 1.0, and the x-axis shows the time in days up to 200. The graph illustrates differences in relapse rates between Duloxetine and placebo over this period.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF). The graph compares placebo to Duloxetine 60/120 mg once daily, showing higher patient improvement percentages at various pain improvement levels for Duloxetine compared to placebo.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A Kaplan-Meier curve chart showing the proportion of patients experiencing relapse over time in days from randomization. The graph compares two treatments: placebo and duloxetine, with duloxetine showing a lower relapse proportion across the timeline up to approximately 250 days.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The graph compares pain improvement outcomes across these groups.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The y-axis shows the percentage of patients improved, ranging from 0 to 100%, and the x-axis shows the percent improvement in pain from baseline, ranging from 0 to 100%. Three lines correspond to each treatment group: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups, showing trends of patient improvement across various pain reduction thresholds.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph showing the percentage of patients improved at various levels of percent pain improvement from baseline. The graph compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and Placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved.*

FDA Label Image

Figure7 (Duloxetine Fig7)

A graph showing the percentage of patients improved versus percent improvement in pain from baseline. The chart compares Duloxetine 60 mg once daily and placebo groups, illustrating higher improvement percentages for Duloxetine across various pain improvement thresholds.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. It contrasts placebo and duloxetine 60/120 mg once daily, showing that duloxetine has a higher percentage of patients improved across various pain improvement thresholds.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares two groups: placebo and Duloxetine 60 mg once daily. The graph indicates higher patient improvement percentages with Duloxetine at various levels of pain improvement.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride showing aromatic rings, oxygen, sulfur, and amine groups consistent with the chemical composition of the active ingredient duloxetine.*

FDA Label Image

Label Image (Lbl500907812)

Label for Duloxetine delayed-release capsules by A-S Medication Solutions, Libertyville, IL. Each capsule contains 20 mg of Duloxetine hydrochloride equivalent to 20 mg Duloxetine. Package includes 90 capsules, stored at 77 degrees Fahrenheit. The label also shows product and lot numbers, dosage instructions, and an NDC of 50090-7812.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.